AIL
NKTR icon

AGF Investments LLC’s Nektar Therapeutics NKTR Stock Holding History

AGF Investments LLC’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-249
Closed -$125K – 685
2019
Q1 		$125K Sell
249
-1,132
-82% -$671K 0.03% 354
2018
Q4 		$681K Buy
1,381
+1,306
+1,741% +$788K 0.09% 196
2018
Q3 		$63K Buy
75
+26
+53% +$22.2K 0.01% 324
2018
Q2 		$35 Buy
49
+25
+104% +$28.8K ﹤0.01% 528
2018
Q1 		$31K Sell
24
-40
-63% -$51.5K 0.01% 398
2017
Q4 		$56K Buy
+64
New +$37.9K 0.01% 232

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

AGF Investments LLC's NKTR Position: Q2 2019 in Review

AGF Investments LLC sold out of Nektar Therapeutics (NKTR) in Q2 2019, closing a stake of 249 shares — an estimated $125K sold.

AGF Investments LLC first reported a position in NKTR in Q4 2017 and held it in 6 quarters. The position peaked at $681K in Q4 2018. 336 funds tracked by Wall St. Rank hold NKTR as of Q2 2019.

  • AGF Investments LLC reported no remaining Nektar Therapeutics position as of Q2 2019 after selling out during the quarter.
  • AGF Investments LLC sold 249 Nektar Therapeutics shares in Q2 2019, an estimated $125K.
  • AGF Investments LLC first reported a position in Nektar Therapeutics in Q4 2017 and held it in 6 quarters.
  • AGF Investments LLC's Nektar Therapeutics position peaked at $681K in Q4 2018.
  • 336 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2019.

Based on AGF Investments LLC's 13F filing for Q2 2019, filed 30 Jul 2019.